

Amendments to the Claims

Claims 1-8 (Cancelled)

Claim 9. (Currently Amended) A method of preventing disease in children and adolescent or adult subjects, which comprises vaccinating the subjects with a booster vaccine composition comprising diphtheria (D), tetanus (T) and acellular pertussis (Pa) antigens and an adjuvant, wherein the concentration of D per 0.5 ml dose of bulk vaccine is 1-4 Lf, the concentration of T per 0.5 ml dose of bulk vaccine does not exceed 10 Lf and the Pa component comprises PT (pertussis toxoid), FHA (filamentous hemagglutinin) and pertactin (69K), wherein the concentration of PT per 0.5 ml dose of bulk vaccine is 2-10 ug, the concentration of FHA per 0.5 ml dose of bulk vaccine is 2-10 ug, and the concentration of 69K is in the range of 0.5 ug to 3 ug per 0.5 ml dose of bulk vaccine, and wherein the booster vaccine is administered following prior administration of a higher dose DTPa vaccine according to any one of claims 1 to 8.

Claim 10. (New) The method of claim 9 wherein the vaccine composition comprises: PT (8ug), FHA (8ug), 69K (2.5ug), D (2.5 Lf) and T (5 Lf) per 0.5 ml dose of bulk vaccine.

Claim 11. (New) The method of claim 9 wherein the vaccine composition comprises one or more additional antigens.

Claim 12. (New) The method of claim 11 wherein an additional antigen is hepatitis B surface antigen.

Claim 13. (New) The method of claim 12 wherein the hepatitis B surface antigen is the S-antigen of HBsAg.

Claim 14. (New) The method of claim 11 wherein an additional antigen is present which provides immunity against one or more of Hib, polio or hepatitis A infection.

Claim 15. (New) The method of claim 9 wherein the adjuvant used in the formulation comprises aluminium hydroxide.

Appln. No.: 09/827,785
Filing Date: April 6, 2001

Cr Claim 16. (New) The method of claim 9, wherein the adjuvant used in the formulation comprises aluminium phosphate.
